The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F FinancialZacks Investment Research • 03/13/26
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained24/7 Wall Street • 03/10/26
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 03/03/26
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-TermZacks Investment Research • 03/02/26
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of ColumbiaBusiness Wire • 03/02/26
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral TherapyBusiness Wire • 02/25/26
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&JInvestors Business Daily • 02/23/26
Gilead pays $7.8bn to take full control of promising multiple myeloma therapyProactive Investors • 02/23/26
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyoutMarket Watch • 02/23/26